This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer Quick Take: Why Alexion Is Ripe for a Deal

NEW YORK ( TheStreet) -- What's the deal with Alexion Pharmaceutical (ALXN - Get Report) -- literally? TheStreet's Jim Cramer and "Mad Money" Research Director Nicole Urken discussed what traders can expect from the drastic acquisition talk surrounding the pharma company.

While the M&A prospects for the broader markets have seemed rather dull this year, biotech has been red hot, with huge acquisitions lighting up the financial headlines throughout 2013.

Both Bloomberg and Reuters have reported that a deal between Alexion and Roche is being talked about and Cramer said that they are not backing down from those claims.

Furthermore, Oppenheimer & Company also expects a deal and have priced it between $148 and $208. The estimates represent a premium of at least 27%, based on the lower end of the estimates' range and from Monday's closing price of $107.93.

Cramer did say that he already thinks Alexion is overvalued, but that he thought that about other pharmaceutical companies that have been takeover targets this year.

While some may argue over valuation, he did conclude, "I gotta believe there's a deal and it's going to be well in excess of where the stock is now."

-- Written by Bret Kenwell in Petoskey, Mich.

Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter. Focuses on short-to-intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
ALXN $155.01 -8.03%
AAPL $125.01 -0.63%
FB $78.10 0.70%
GOOG $524.22 -1.24%
TSLA $230.43 -1.08%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs